Quantcast
Last updated on April 21, 2014 at 9:20 EDT

Latest Cipher Pharmaceuticals Inc. Stories

2012-11-26 08:25:01

PRINCETON, N.J., Nov. 26, 2012 /PRNewswire/ -- Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the sales and promotion launch of Absorica (Isotretinoin) Capsules, a product that is licensed from Cipher Pharmaceuticals Inc. of Mississauga, Ontario. Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Due to its high lipophilicity, oral absorption of isotretinoin is...

2012-07-31 06:25:57

HAMILTON, N.J., July 31, 2012 /PRNewswire/ -- MedAvante, Inc., the world's leading provider of centralized assessments in clinical trials of treatments for central nervous system (CNS) disorders, announced that MedAvante Central Ratings, used to assess the potential for psychiatric side effects in a non-psychiatric clinical program, was deemed an acceptable methodology for signal detection in a New Drug Application (NDA) approved recently by the U.S. Food and Drug Administration (FDA)....

2012-05-29 06:24:38

PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals Inc., RLI is expected to launch Absorica(TM) in the...

2012-05-28 02:20:52

Product to be launched as Absorica(TM)  Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.  Absorica is expected to be launched in the U.S. in Q4 2012. "Approval...

2012-05-27 18:20:10

Product to be launched as Absorica(TM)  Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.  Absorica is expected to be launched in the U.S. in Q4 2012. "Approval...

2011-06-29 07:30:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, June 29, 2011 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc. ("Vertical"), a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States. CIP-TRAMADOL ER is a...

2011-06-07 07:00:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, June 7, 2011 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND) today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.  The 925-patient study was a randomized, double-blinded trial comparing the safety profile of CIP-ISOTRETINOIN to a commercially available isotretinoin...

2010-12-07 10:35:00

HAMILTON, N.J., Dec. 7, 2010 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study. Cipher recently announced the completion of the patient enrollment phase of their clinical study, in which every patient is interviewed by a qualified MedAvante mental health expert at every visit of the study....

2010-10-29 07:30:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug...

2010-05-10 06:00:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 10 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced the U.S. Food and Drug Administration ("FDA") has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. "This represents our second FDA approval - a major achievement for the Company that reflects a significant amount of effort and dedication from our team, led...